Research

ATLAS S-ICD

Official Title

Avoid Transvenous Leads in Appropriate Subjects

Status

Ongoing

Overview

To evaluate whether a subcutaneous implantable cardioverter defibrillator (ICD) reduces perioperative complications compared to a transvenous ICD, using a composite safety outcome.

Study Design

This study is a multi-centre, randomized, open-label parallel group clinical trial.

Primary Endpoint

The primary safety endpoint will be measured at 6 months following ICD implantation, and will be a composite of lead-related perioperative complications.

Number of Patients

500

Number of Sites

20

Number of Countries

1

Study Period

2016-2020

Principal Investigator

Jeff Healey

Program Manager

Kimberly Begley

Research Coordinator

Angie Djuric, Andrea Ling

Collaborators

Boston Scientific